Purchase this article with an account.
Anna Plyukhova, Maria Karpilova, Aleksey Kuznetsov, Irina Andreeva, Olga Gabina, Maria Budzinskaya, Valery Erichev, Sergey Avetisov; Intraocular pressure monitoring in patients with ranibizumab development. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6303.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the posture-induced intraocular pressure (IOP) changes after endovitreal injection of ranibizumab in AMD patients and a combination of AMD and glaucoma.
We examined 71 patients (71 eyes) with exudative form of AMD, of whom 11 in conjunction with primary open-angle medical treatment compensation form glaucoma in one case, after antiglaucoma surgery. Each eye received a single intravitreal injection of 0.5 mg ranibizumab.. The IOP was measured minute prior to the ingestion 1, 30 and 180 minutes after using the iCare ONE home tonometer(Finland)
1 and 2 of IOP elevation patients was detected in a minute after injection of ranibizumab, up to 60 mm Hg and smooth its decline to 30 minutes. By 180 minutes after drug administration level IOP returned to normal only in patients in group I. In patients with combined pathology after 3 hours IOP remained above baseline. These differences between the groups were statistically significant.
Ranibizumab treatment causes an increase IOP in both groups, followed by a decline, and these variations are comparable. In the group with comorbidity level of IOP does not reach baseline, though, and within the age norm.
This PDF is available to Subscribers Only